Matches in Wikidata for { <http://www.wikidata.org/entity/Q83145997> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q83145997 description "article scientifique publié en 2011" @default.
- Q83145997 description "artículu científicu espublizáu n'avientu de 2011" @default.
- Q83145997 description "scientific article published on 27 December 2011" @default.
- Q83145997 description "wetenschappelijk artikel" @default.
- Q83145997 description "наукова стаття, опублікована в грудні 2011" @default.
- Q83145997 name "Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer" @default.
- Q83145997 name "Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer" @default.
- Q83145997 type Item @default.
- Q83145997 label "Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer" @default.
- Q83145997 label "Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer" @default.
- Q83145997 prefLabel "Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer" @default.
- Q83145997 prefLabel "Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer" @default.
- Q83145997 P1433 Q83145997-0A9B3DB7-F9F7-4D39-8363-749D78A87BA8 @default.
- Q83145997 P1476 Q83145997-27EEFF28-134B-4022-83C2-25E08130BFB3 @default.
- Q83145997 P2093 Q83145997-00BC2996-27FD-49A6-B2E7-932FA0253BA9 @default.
- Q83145997 P2093 Q83145997-367C60DD-4031-4E3E-95BE-E2868059B61D @default.
- Q83145997 P2093 Q83145997-58957EF4-9630-4DE2-9BEC-B5160FA10C4D @default.
- Q83145997 P2093 Q83145997-5F9AFC31-30F6-426A-80EF-F430E9673E57 @default.
- Q83145997 P2093 Q83145997-6F7AEFD5-CF69-4F52-873F-B911B63F721A @default.
- Q83145997 P2093 Q83145997-70AEF938-0B5D-4D42-B22C-D5E0B6879F05 @default.
- Q83145997 P2093 Q83145997-7CA76D7A-12C3-43F7-8C82-24EFA51DAA10 @default.
- Q83145997 P2093 Q83145997-99FC3106-19FA-4BC0-93AB-ACA64C1F366D @default.
- Q83145997 P2093 Q83145997-A2937D65-33CA-4450-A53B-9C4BC8A69F28 @default.
- Q83145997 P2093 Q83145997-D612E419-5C4D-483D-BFBD-9E56F3877BA0 @default.
- Q83145997 P2093 Q83145997-DCE5DB8C-8958-4DB3-94E6-6F06A37735F6 @default.
- Q83145997 P2093 Q83145997-E0C77414-6C54-41F3-BCC7-ACAF76363439 @default.
- Q83145997 P2093 Q83145997-FBFB9A91-E50D-46F5-B78D-66DCB77EB0DE @default.
- Q83145997 P304 Q83145997-6104A207-A550-4E5A-899D-0E3544ACF993 @default.
- Q83145997 P31 Q83145997-C3859064-A395-4AA2-9200-E69EF45475BB @default.
- Q83145997 P356 Q83145997-5726D744-192D-4879-A105-831D9E6D073C @default.
- Q83145997 P433 Q83145997-941CEF8D-1BAB-44DD-B6AF-BC415C8212DE @default.
- Q83145997 P478 Q83145997-5FBC8498-D141-4B03-965D-B5673F17D00D @default.
- Q83145997 P50 Q83145997-9641DD7B-1785-453A-A419-98130ACADF9B @default.
- Q83145997 P50 Q83145997-A59F0D26-FA0F-4444-99FA-5B52F77E7A13 @default.
- Q83145997 P50 Q83145997-E14992D0-6E20-4C74-82E8-6A8A8EB85C9E @default.
- Q83145997 P577 Q83145997-C577EE51-9046-425D-B13E-AC7D7939B620 @default.
- Q83145997 P698 Q83145997-D54FEA2B-7873-43C2-B967-1C6957996F4B @default.
- Q83145997 P921 Q83145997-3CD142FD-3B82-4D9B-81D3-29D5866C9737 @default.
- Q83145997 P921 Q83145997-EE442682-B9B5-49D5-9A08-F77DF1D01161 @default.
- Q83145997 P921 Q83145997-EE871253-3FEC-4B81-805F-6482A26C1DDA @default.
- Q83145997 P356 JCO.2011.36.9215 @default.
- Q83145997 P698 22203755 @default.
- Q83145997 P1433 Q400292 @default.
- Q83145997 P1476 "Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer" @default.
- Q83145997 P2093 "Amit Amnon" @default.
- Q83145997 P2093 "Bella Kaufman" @default.
- Q83145997 P2093 "Beth Y Karlan" @default.
- Q83145997 P2093 "Charlie Gourley" @default.
- Q83145997 P2093 "Elizabeth S Lowe" @default.
- Q83145997 P2093 "James Carmichael" @default.
- Q83145997 P2093 "Joo Ern Ang" @default.
- Q83145997 P2093 "Katherine M Bell-McGuinn" @default.
- Q83145997 P2093 "Lee-May Chen" @default.
- Q83145997 P2093 "Mark Wickens" @default.
- Q83145997 P2093 "Michael Friedlander" @default.
- Q83145997 P2093 "Stan B Kaye" @default.
- Q83145997 P2093 "Tamar Safra" @default.
- Q83145997 P304 "372-379" @default.
- Q83145997 P31 Q13442814 @default.
- Q83145997 P356 "10.1200/JCO.2011.36.9215" @default.
- Q83145997 P433 "4" @default.
- Q83145997 P478 "30" @default.
- Q83145997 P50 Q116996864 @default.
- Q83145997 P50 Q11718282 @default.
- Q83145997 P50 Q89808263 @default.
- Q83145997 P577 "2011-12-27T00:00:00Z" @default.
- Q83145997 P698 "22203755" @default.
- Q83145997 P921 Q172341 @default.
- Q83145997 P921 Q18936 @default.
- Q83145997 P921 Q7083106 @default.